Sanjoy et al. reported that cardiovascular outcomes significantly improved in patients with T2D who received exenatide (a GLP-1 receptor agonist) or exenatide plus insulin compared to those receiving insulin only [19]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.